Biologix Hair Inc. Establishes Medical Advisory Board; Dr. Craig Ziering Appointed as Chairman
Toronto, Ontario – April 17, 2013 – Biologix Hair Inc. (OTCBB: BLGX; OTCQB: BLGX) announces the Company has established a Medical Advisory Board and named Dr. Craig Ziering as its Chairman.
Dr. Ziering received his Doctorate of Osteopathic Medicine from Nova Southeastern University in Miami, Florida and completed his residency at Ohio University’s Grandview Medical Center, Dayton, Ohio. After completing a Fellowship in Hair Restoration with Medical Hair Restoration in Orlando, Dr. Ziering became the Associate Medical Director at MHR for a period of ten years before founding his private practice, Ziering Medical. Dr. Ziering is certified by both the American Board of Hair Restoration Surgery and the American Osteopathic Board of Dermatology.
A past president of the American Osteopathic College of Dermatology, Dr. Ziering serves on advisory boards for various companies including Merck, Lexington International, Pfizer and on the scientific advisory board of Histogen (Regenerative Medicine) and is on the Surgical Faculty for the Procedural Dermatology Fellowship at the University of California at Irvine, the Dermatology Faculty, Western University/Pacific Hospital, Long Beach, California and Michigan State University, Dermatology Faculty. Additionally, Dr. Ziering is the Medical Director for Advanced Hair Growth and Apira Science as well as being the Primary Investigator for the clinical trials involving hair cloning and multiplication. In 2003, Dr. Ziering was recognized by his peers at the International Society for Hair Restoration Surgeons for his Whorl Hair Classification System being awarded the prestigious, “Most Original New Idea” at that year’s scientific assembly.
Ron Holland, Biologix Director and CEO, stated, "As we continue to rapidly develop our international network of clinicians and medical practitioners seeking to become certified Biologix Hair Therapists™ and to secure exclusive territorial treatment rights for the Biologix Hair Therapy System™, we deem it of great value to build a Medical Advisory Board comprised of leading medical professionals who can provide ongoing advice and assistance.
"Dr. Ziering is one of the contracting clinicians who recognized the value opportunity of our patent-pending hair formula, Biologix Revive. We welcome Dr. Ziering to the Biologix team and look forward to working together to build a top-notch board of medical advisers.”
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss formula – Biologix Revive – and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.
Additionally, on May 11, 2012, Venable LLC, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 144 countries have as of now contracted, including Canada and the United States.
Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™, if and when FDA and other major market approvals are forthcoming.
As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.
Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted. Therefore, the Biologix Hair Therapy System™ is not yet available other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.
To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.
Contact info for Biologix Hair Inc.
Corporate Communications
Toll Free: +1 855.292.8585
Phone: +1 647.494.8001
Email:
CorporateCommunications@BiologixHair.com
Web:
www.BiologixHair.com
Disclaimer
Reply With Quote
Originally Posted by Buster
Bookmarks